Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549719 | 1.00 | GBA1 (0.40) | GBA1MBOAT4ATMGABRA5GRM2 | |
| SCHEMBL14658492 | 0.88 | DUT (0.39) | GBA1MBOAT4KDM4EALDH1A1DUT | |
| SCHEMBL13936233 | 0.85 | GBA1 (0.37) | GBA1MBOAT4GRM2KDM4EALDH1A1 | |
| SCHEMBL4764169 | 0.83 | DUT (0.37) | GBA1MBOAT4KDM4EALDH1A1DUT | |
| SCHEMBL4772134 | 0.82 | DUT (0.36) | GBA1MBOAT4KDM4EALDH1A1DUT | |
| SCHEMBL17810295 | 0.81 | SYK (0.39) | GABRA5KDM4EBACE1DUT | |
| SCHEMBL29185149 | 0.81 | ESR1 (0.44) | BACE1DUT | |
| SCHEMBL20757569 | 0.80 | DRD2 (0.33) | — | |
| SCHEMBL31132916 | 0.79 | MBOAT4 (0.37) | MBOAT4ATMGABRA5GRM2KDM4E | |
| SCHEMBL29187084 | 0.79 | CNR2 (0.39) | MBOAT4GABRA5BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4745134-A1 | PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12509454-B2 | Thiadiazolyl derivatives | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4079734-B1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025016323-A1 | PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2025-01-23 | — | — | WO | disclosed |
| US-20240166624-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2024-05-23 | — | — | US | disclosed |
| CN-114302886-B | Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-1873153-B1 | 3-AZETIDINECARBOXYLIC ACID DERIVATIVES FOR USE AS IMMUNOSUPPRESSANTS | DAIICHI SANKYO CO LTD (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-7687491-B2 | Heterocyclic compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20080113961-A1 | Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1873153-A1 | HETEROCYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
| US-20070093473-A1 | 7-Heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents | GLAXO GROUP LIMITED | 2007-04-26 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | GBA1 4098/4885MBOAT4 884/4885ATM 3885/4885 |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | GBA1 2741/4885MBOAT4 4391/4885ATM 404/4885 |
| US-20240166624-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | GBA1 3163/4885MBOAT4 554/4885ATM 2812/4885 |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLH | GBA1 3463/4885MBOAT4 4171/4885ATM 332/4885 |
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | GBA1 1758/4885MBOAT4 2335/4885ATM 1532/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | GBA1 2531/4885MBOAT4 3919/4885ATM 4591/4885 |
| US-20070093473-A1 | 7-Heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents | SIGMAR1, CHRNA3, CHRNA5 | GBA1 2535/4885MBOAT4 3031/4885ATM 4702/4885 |
| US-20080113961-A1 | Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds | TPMT, AZI2, IDO1 | GBA1 1992/4885MBOAT4 4080/4885ATM 4753/4885 |
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | GBA1 3301/4885MBOAT4 3144/4885ATM 2444/4885 |
| US-12509454-B2 | Thiadiazolyl derivatives | POLD1, POLQ, DNA2 | GBA1 4005/4885MBOAT4 4408/4885ATM 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.